Table: Nxera Pharma 6-MTH group results (IFRS)

Nxera Pharma

07/08/2026 07:40

   Aug 7 (Reuters)- 
              Nxera Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended       Year to 
                  Jun 30, 2026        Jun 30, 2025     Dec 31, 2026 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales               18.91               15.09                     
                   (+25.3 pct)         (+18.7 pct)                  
  Operating            1.88             loss 2.76                   
  Pretax               1.40             loss 3.72                   
  Net                  1.59             loss 3.14                   
  EPS Basic         17.54 yen        loss 34.82 yen                 
  EPS Diluted       15.86 yen        loss 34.82 yen                 
  Ann Div                                  NIL              NIL     
  -Q2 Div              NIL                 NIL                      
  -Q4 Div                                  NIL              NIL     
 
  NOTE - Nxera Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T